Using sophisticated techniques to sample and analyze airborne molecules in the odors from human skin cells, scientists in the US were able to detect a unique chemical signature for melanoma, the deadliest form of skin cancer... […]

Advanced metastatic melanoma is a disease that has proven difficult to eradicate. Despite the success of melanoma-targeting drugs, tumors inevitably become drug resistant and return, more aggressive than before... […]

Using DNA sequencing, researchers in the UK have discovered possible new treatment targets for a rare form of cancer known as mucosal melanoma. The more we know of the sub-types of melanoma, the more we can tailor treatment for patients and improve their prospects, says Cancer Research UK, a core sponsor of the center where the research took place... […]

Solar radiation in Spain has increased by 2.3% every decade since the 1980s, according to a study by researchers from the University of Girona and the Federal Institute of Technology (ETH) in Zurich. This increase is linked to the decreased presence of clouds, which has increased the amount of direct radiation reaching us from the Sun... […]

Scientists are reporting development and successful lab tests on the first potential drug to pack a lethal one-two punch against melanoma skin cancer cells. Hit number one destroys cells in the main tumor, and the second hit blocks the spread of the cancer to other sites in the body, according to their report in the journal ACS Chemical Biology... […]

Daily sunscreen use greatly reduces skin aging, even in middle-aged men and women, according to new research in the Annals of Internal Medicine. Sunscreen and antioxidants have historically been shown to prevent skin aging, however, there has been no scientific evidence of their effectiveness... […]

Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer. The results were presented at the 2013 meeting of the American Society of Clinical Oncology today in Chicago by Dr... […]

The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented at the 49th annual meeting of the American Society of Clinical Oncology (ASCO). The findings are potentially practice-changing for a […]

A new drug being tested in patients with advanced melanoma, the most dangerous form of skin cancer, has shown significant antitumor activity, according to preliminary results of a new study. The research, conducted by a team of experts from UCLA's Jonsson Comprehensive Cancer Center, led by Dr... […]

AstraZeneca's experimental drug, selumetinib, is the first targeted medication to show a significant clinical benefit for patients with melanoma of the eye (metastatic uveal melanoma), researchers from the Memorial Sloan-Kettering Cancer Center explained at the 49th annual meeting of the American Society of Clinical Oncology (ASCO), in Chicago, Illinois […]